Clinical Outcomes and Economic Characteristics Regarding Inpatient Treatment of Brain Tumors with Implantable Wafers in the United States

• Main Authors: Culver, Mark, VandenBerg, Justin, Skrepnek, Grant
• Language: en_US
• Published: The University of Arizona. 2012
• Subjects: Outcomes; Treatment; Brain Tumors; Implantable Wafers; United States; Agency for Healthcare Research and Quality (AHRQ); Healthcare Cost and Utilization Project (HCUP)
• Online Access: http://hdl.handle.net/10150/614463; http://arizona.openrepository.com/arizona/handle/10150/614463

Class of 2012 Abstract === Specific Aims: This study was aimed to evaluate inpatient clinical treatment characteristics associated with the use of intracranial implantation of chemotherapeutic wafers for malignant brain neoplasms within United States, and assess inpatient mortality and total charges regarding treatment with wafer versus without. Methods: A retrospective cohort investigation was conducted utilizing inpatient discharge records from the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample from 2005 to 2009. From this nationally-representative sample, 9,455 adults aged 18 years or older were identified with malignant neoplasms of the brain treated with implantable chemotherapeutic wafers. Outcomes of inpatient mortality and charges were assessed via multivariate regression analysis, controlling for patient characteristics, hospital structure, comorbidities, and clinical complications. Main Results: The average age of patients with brain neoplasms was 56.6 (±16.5) years, and of those patients, 42.9% were female. The odds ratio for inpatient mortality of patients treated with implantable chemotherapeutic wafers was OR=0.380 (P<0.001), and patients that received wafer treatment had increased charges exp(b)=2.147 (P<0.001). Conclusions: Multiple factors were associated with inpatient mortality and charges among the 247,829 patients that were diagnosed with malignant brain neoplasms from 2005-2009. With regards to these patients, implantable chemotherapeutic wafers were associated with increased inpatient survival and increased charges.